Document Detail

Lipid management: considerations in acute coronary syndrome.
MedLine Citation:
PMID:  18611369     Owner:  NLM     Status:  MEDLINE    
Managing dyslipidemia is an important part of the primary and secondary prevention of coronary heart disease. Low-density lipoprotein cholesterol reduction remains the primary lipid goal. Patients who have experienced an acute coronary syndrome (ACS) are at very high risk of recurrent adverse cardiovascular events. A growing body of literature supports the concept that early and intensive treatment with statins after an ACS event decreases recurrent adverse cardiovascular events. We review available evidence pertaining to lipid alterations in ACS.
Venkateshwar R Polsani; Salim S Virani; Vijay Nambi
Related Documents :
3394509 - Plasma lipid and apolipoprotein levels in children hereditarily predisposed to coronary...
1980699 - Do benzodiazepines have a role in the prevention or treatment of coronary heart disease...
17721009 - Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: suba...
9732899 - Underutilization of lipid-lowering drugs in older persons with prior myocardial infarct...
11122689 - Recent developments in the treatment of hypertriglyceridemia.
16397139 - Hepatic lipase deficiency delays atherosclerosis, myocardial infarction, and cardiac dy...
15746449 - Early recanalization rates and clinical outcomes in patients with tandem internal carot...
3111239 - Coronary arteriography in the intact rabbit: demonstration of coronary vasomotor and el...
16943109 - Similar pattern of diastolic function adaptation of both ventricles to programmed atrio...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current cardiology reports     Volume:  10     ISSN:  1534-3170     ISO Abbreviation:  Curr Cardiol Rep     Publication Date:  2008 Jul 
Date Detail:
Created Date:  2008-07-09     Completed Date:  2008-10-24     Revised Date:  2009-04-16    
Medline Journal Info:
Nlm Unique ID:  100888969     Medline TA:  Curr Cardiol Rep     Country:  United States    
Other Details:
Languages:  eng     Pagination:  334-41     Citation Subset:  IM    
Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acute Coronary Syndrome / blood,  drug therapy*
Anticholesteremic Agents / therapeutic use
Cholesterol, LDL / drug effects
Dyslipidemias / drug therapy*
Heptanoic Acids / therapeutic use
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Pravastatin / therapeutic use
Pyrroles / therapeutic use
Risk Assessment
Risk Factors
Triglycerides / blood
Reg. No./Substance:
0/Anticholesteremic Agents; 0/Cholesterol, LDL; 0/Heptanoic Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Pyrroles; 0/Triglycerides; 110862-48-1/atorvastatin; 81093-37-0/Pravastatin
Republished in:
Curr Atheroscler Rep. 2009 Mar;11(2):149-56   [PMID:  19228490 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Antiplatelet therapy in acute coronary syndromes.
Next Document:  Protein-protein interactions in the membrane: sequence, structural, and biological motifs.